{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:54:43Z","timestamp":1759366483259,"version":"build-2065373602"},"reference-count":115,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.revmed.2019.05.016","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:08:35Z","timestamp":1562803715000},"page":"654-663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Actualit\u00e9s dans la physiopathologie de la scl\u00e9rodermie syst\u00e9mique\u00a0: vers de nouvelles opportunit\u00e9s th\u00e9rapeutiques"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-9146","authenticated-orcid":false,"given":"K.","family":"Didier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Antonicelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.N.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Servettaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib0575","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"suppl 10","key":"10.1016\/j.revmed.2019.05.016_bib0580","article-title":"Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3\u00a0Randomized Controlled Trial","volume":"70","author":"Khanna","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2019.05.016_bib0585","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","article-title":"Geoepidemiology of systemic sclerosis","volume":"9","author":"Ranque","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib0590","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/BOR.0000000000000214","article-title":"Genetics of systemic sclerosis: recent advances","volume":"27","author":"Ramos","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.revmed.2019.05.016_bib0595","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/art.11173","article-title":"Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies","volume":"48","author":"Feghali-Bostwick","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2019.05.016_bib0600","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00281-015-0504-6","article-title":"Epigenetics and systemic sclerosis","volume":"37","author":"Altorok","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.revmed.2019.05.016_bib0605","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.biopha.2016.12.072","article-title":"Epigenetic modifications and epigenetic based medication implementations of autoimmune diseases","volume":"87","author":"Ahmadi","year":"2017","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"issue":"12","key":"10.1016\/j.revmed.2019.05.016_bib0610","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0891-5849(03)00149-7","article-title":"Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis","volume":"34","author":"Fubini","year":"2003","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0615","first-page":"97","article-title":"Occupational exposure to solvents and gender-related risk of systemic sclerosis: a metaanalysis of case-control studies","volume":"34","author":"Kettaneh","year":"2007","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.revmed.2019.05.016_bib0620","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM200003163421105","article-title":"Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases","volume":"342","author":"Janowsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.05.016_bib0625","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1084\/jem.175.4.1103","article-title":"Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes","volume":"175","author":"Muryoi","year":"1992","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0630","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/80533","article-title":"Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94\u00a0and induce apoptosis in human endothelial cells","volume":"6","author":"Lunardi","year":"2000","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0635","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.pmed.0030002","article-title":"Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach","volume":"3","author":"Lunardi","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.revmed.2019.05.016_bib0640","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaut.2016.06.009","article-title":"A clinical update on the significance of the gut microbiota in systemic autoimmunity","volume":"74","author":"Rosser","year":"2016","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0645","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kep226","article-title":"Small intestinal bacterial overgrowth in systemic sclerosis","volume":"48","author":"Marie","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib0650","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/art.39572","article-title":"Association of systemic sclerosis with a unique colonic microbial consortium","volume":"68","author":"Volkmann","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0655","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13075-016-1182-z","article-title":"Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease","volume":"18","author":"Andr\u00e9asson","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.revmed.2019.05.016_bib0660","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.revmed.2017.05.003","article-title":"D\u00e9pistage de l\u2019hypertension pulmonaire au cours de la scl\u00e9rodermie syst\u00e9mique\u00a0: une strat\u00e9gie optimale encore \u00e0 d\u00e9finir","volume":"38","author":"Launay","year":"2017","journal-title":"Rev Med Interne"},{"issue":"3","key":"10.1016\/j.revmed.2019.05.016_bib0665","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.rdc.2015.04.008","article-title":"Scleroderma renal crisis","volume":"41","author":"Guillevin","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"10.1016\/j.revmed.2019.05.016_bib0670","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3899\/jrheum.160791","article-title":"Evidence for a derangement of the microvascular system in patients with a very early diagnosis of systemic sclerosis","volume":"44","author":"Chora","year":"2017","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0675","first-page":"1838","article-title":"Circulating endothelin-1\u00a0levels in systemic sclerosis subsets\u2013a marker of fibrosis or vascular dysfunction?","volume":"21","author":"Vancheeswaran","year":"1994","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib0680","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10067-004-0987-3","article-title":"Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1\u00a0in patients with systemic sclerosis: relationship to organ systemic involvement","volume":"24","author":"Kuryliszyn-Moskal","year":"2005","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2019.05.016_bib0685","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/03009742.2014.887768","article-title":"Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89\u00a0patients treated since specific approval","volume":"43","author":"Agard","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"10.1016\/j.revmed.2019.05.016_bib0690","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0695","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/ard.2006.064493","article-title":"Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control","volume":"66","author":"Pignone","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0700","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/40.10.1089","article-title":"Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte\/macrophage cells","volume":"40","author":"Allanore","year":"2001","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib0705","first-page":"169","article-title":"Endothelial nitric oxide gene polymorphism and risk of systemic sclerosis: predisposition effect of T-786C promoter and protective effect of 27bp repeats in Intron 4","volume":"28","author":"Sinici","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0710","first-page":"4","article-title":"The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis","volume":"19","author":"Herrick","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0715","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.revmed.2019.05.016_bib0720","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.0409781102","article-title":"The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles","volume":"102","author":"Distler","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.revmed.2019.05.016_bib0725","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1590\/S0100-879X2004000900018","article-title":"Correlation between serum E-selectin levels and panoramic nailfold capillaroscopy in systemic sclerosis","volume":"37","author":"Valim","year":"2004","journal-title":"Braz J Med Biol Res"},{"issue":"451.","key":"10.1016\/j.revmed.2019.05.016_bib0730","article-title":"Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis","volume":"10","author":"Maugeri","year":"2018","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib0735","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar596","article-title":"Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers","volume":"4","author":"Distler","year":"2002","journal-title":"Arthritis Res"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib0740","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.38953","article-title":"Elevated levels of pentraxin 3\u00a0in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis","volume":"67","author":"Shirai","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"4","key":"10.1016\/j.revmed.2019.05.016_bib0745","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1529-0131(200004)43:4<889::AID-ANR21>3.0.CO;2-5","article-title":"Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis","volume":"43","author":"Hebbar","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.revmed.2019.05.016_bib0750","first-page":"2565","article-title":"Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1\u00a0in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation","volume":"29","author":"Macko","year":"2002","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2019.05.016_bib0755","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4\u00a0as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.05.016_bib0760","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mvr.2015.01.004","article-title":"Decreased numbers of endothelial progenitor cells in patients in the early stages of systemic sclerosis","volume":"98","author":"Andrigueti","year":"2015","journal-title":"Microvasc Res"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0765","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/ard.2007.082131","article-title":"Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity","volume":"67","author":"Avouac","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"10.1016\/j.revmed.2019.05.016_bib0770","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1161\/CIRCULATIONAHA.108.787200","article-title":"Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells","volume":"118","author":"Zhu","year":"2008","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.revmed.2019.05.016_bib0775","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1002\/art.30536","article-title":"Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells","volume":"63","author":"Avouac","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.revmed.2019.05.016_bib0780","first-page":"462","article-title":"Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension","volume":"25","author":"Negi","year":"1998","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0785","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1172\/JCI118377","article-title":"IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines","volume":"97","author":"Carvalho","year":"1996","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.revmed.2019.05.016_bib0790","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/1529-0131(200011)43:11<2550::AID-ANR24>3.0.CO;2-H","article-title":"Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95","volume":"43","author":"Sgonc","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0795","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.150061","article-title":"Autoantibodies against endothelin 1\u00a0type a receptor are strong predictors of digital ulcers in systemic sclerosis","volume":"42","author":"Avouac","year":"2015","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib0800","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4503","article-title":"Angiotensin receptor type 1\u00a0and endothelin receptor type A on immune cells mediate migration and the expression of IL-8\u00a0and CCL18\u00a0when stimulated by autoantibodies from systemic sclerosis patients","volume":"16","author":"G\u00fcnther","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.revmed.2019.05.016_bib0805","first-page":"892","article-title":"Increased CD226\u00a0Expression on CD8+ T Cells Is Associated with Upregulated Cytokine Production and Endothelial Cell Injury in Patients with Systemic Sclerosis","volume":"195","author":"Ayano","year":"2015","journal-title":"J Immunol Baltim Md 1950"},{"issue":"Suppl 5","key":"10.1016\/j.revmed.2019.05.016_bib0810","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/rheumatology\/ken278","article-title":"Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?","volume":"47","author":"Abraham","year":"2008","journal-title":"Rheumatol Oxf Engl"},{"issue":"7","key":"10.1016\/j.revmed.2019.05.016_bib0815","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tcm.2012.05.011","article-title":"Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant","volume":"21","author":"Manetti","year":"2011","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.revmed.2019.05.016_bib0820","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/CIRCRESAHA.111.242057","article-title":"Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis","volume":"109","author":"Manetti","year":"2011","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.revmed.2019.05.016_bib0825","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/art.1780341204","article-title":"Endothelial and fibroblastic activation in scleroderma. The myth of the \u00ab\u00a0uninvolved skin\u00a0\u00bb","volume":"34","author":"Claman","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.revmed.2019.05.016_bib0830","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1074\/jbc.270.7.3423","article-title":"Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1","volume":"270","author":"Kirk","year":"1995","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.revmed.2019.05.016_bib0835","doi-asserted-by":"crossref","first-page":"R1113","DOI":"10.1186\/ar1790","article-title":"Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis","volume":"7","author":"Rajkumar","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.revmed.2019.05.016_bib0840","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/exd.12619","article-title":"Fli1\u00a0deficiency and beyond: a unique pathway linking peripheral vasculopathy and dermal fibrosis in systemic sclerosis","volume":"24","author":"Manetti","year":"2015","journal-title":"Exp Dermatol"},{"issue":"25","key":"10.1016\/j.revmed.2019.05.016_bib0845","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0850","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/(SICI)1096-9896(199801)184:1<4::AID-PATH968>3.0.CO;2-0","article-title":"TGF beta \u2013 a role in systemic sclerosis?","volume":"184","author":"Cotton","year":"1998","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0855","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1523-1747.1998.00073.x","article-title":"Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype","volume":"110","author":"Kawakami","year":"1998","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.revmed.2019.05.016_bib0860","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/art.11157","article-title":"Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts","volume":"48","author":"Mori","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.revmed.2019.05.016_bib0865","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0870","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0002-9440(10)63289-0","article-title":"Targeted disruption of TGF-beta\/Smad3\u00a0signaling modulates skin fibrosis in a mouse model of scleroderma","volume":"165","author":"Lakos","year":"2004","journal-title":"Am J Pathol"},{"issue":"42","key":"10.1016\/j.revmed.2019.05.016_bib0875","doi-asserted-by":"crossref","first-page":"40967","DOI":"10.1074\/jbc.M307380200","article-title":"Identification of PLOD2\u00a0as telopeptide lysyl hydroxylase, an important enzyme in fibrosis","volume":"278","author":"van der Slot","year":"2003","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.revmed.2019.05.016_bib0880","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/1529-0131(200107)44:7<1667::AID-ART291>3.0.CO;2-Y","article-title":"Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts","volume":"44","author":"Santiago","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0885","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am J Pathol"},{"issue":"suppl 10","key":"10.1016\/j.revmed.2019.05.016_bib0890","article-title":"A Phase 2\u00a0Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2\u00a0Agonist, in Diffuse Cutaneous Systemic Sclerosis","volume":"69","author":"Spiera","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.revmed.2019.05.016_bib0895","article-title":"Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2\u00a0Study in Diffuse Cutaneous Systemic Sclerosis Subjects","volume":"70","author":"Spiera","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2019.05.016_bib0900","doi-asserted-by":"crossref","first-page":"w13050","DOI":"10.4414\/smw.2010.13050","article-title":"Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?","volume":"140","author":"Beyer","year":"2010","journal-title":"Swiss Med Wkly"},{"issue":"11","key":"10.1016\/j.revmed.2019.05.016_bib0905","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2\u00a0mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"10.1016\/j.revmed.2019.05.016_bib1140","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0910","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/art.22927","article-title":"Presence of CD4+ CD8+ double-positive T cells with very high interleukin-4\u00a0production potential in lesional skin of patients with systemic sclerosis","volume":"56","author":"Parel","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib0915","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L","article-title":"Production of type 2\u00a0cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis","volume":"42","author":"Atamas","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0920","doi-asserted-by":"crossref","first-page":"R10","DOI":"10.1186\/ar1860","article-title":"Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts","volume":"8","author":"Chizzolini","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.revmed.2019.05.016_bib0925","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1002\/art.24049","article-title":"Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4","volume":"58","author":"Fineschi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.revmed.2019.05.016_bib0930","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/labinvest.2017.23","article-title":"Endothelial cell-specific activation of transforming growth factor-\u03b2 signaling in mice induces cutaneous, visceral, and microvascular fibrosis","volume":"97","author":"Wermuth","year":"2017","journal-title":"Lab Investig J Tech Methods Pathol"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib0935","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1136\/annrheumdis-2013-203535","article-title":"Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis","volume":"73","author":"Maurer","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2019.05.016_bib0940","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib0945","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2011-200862","article-title":"Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis","volume":"71","author":"Beyer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"10.1016\/j.revmed.2019.05.016_bib0950","article-title":"The Effects of Riociguat on Raynaud's Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study","volume":"70","author":"Khanna","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.revmed.2019.05.016_bib0955","article-title":"Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)","volume":"70","author":"Distler","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib0960","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.revmed.2016.02.016","article-title":"Role of B cells in the pathogenesis of systemic sclerosis","volume":"38","author":"Sanges","year":"2017","journal-title":"Rev Med Interne"},{"issue":"25","key":"10.1016\/j.revmed.2019.05.016_bib0965","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.revmed.2019.05.016_bib0970","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.revmed.2019.05.016_bib0975","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.revmed.2019.05.016_bib0980","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"9790","key":"10.1016\/j.revmed.2019.05.016_bib0985","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2\u00a0trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet Lond Engl"},{"issue":"24","key":"10.1016\/j.revmed.2019.05.016_bib0990","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A Randomized Clinical Trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2019.05.016_bib0995","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3389\/fimmu.2018.02938","article-title":"Mesenchymal stem cells in systemic sclerosis: allogenic or autologous approaches for therapeutic use?","volume":"9","author":"Rozier","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2019.05.016_bib1000","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2015.00496","article-title":"Systemic Sclerosis patients present alterations in the expression of molecules involved in B-Cell regulation","volume":"6","author":"Soto","year":"2015","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.revmed.2019.05.016_bib1005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","article-title":"Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity","volume":"13","author":"Lanteri","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.revmed.2019.05.016_bib1010","first-page":"2056","article-title":"Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF","volume":"34","author":"Matsushita","year":"2007","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2019.05.016_bib1015","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","article-title":"B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib1020","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.revmed.2019.05.016_bib1025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fimmu.2018.00541","article-title":"Autoantibodies associated with connective tissue diseases: what meaning for clinicians?","volume":"9","author":"Didier","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib1030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.1780270607","article-title":"Medsger TA, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations","volume":"27","author":"Roumm","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.revmed.2019.05.016_bib1035","first-page":"3649","article-title":"cell expansion in the skin of patients with systemic sclerosis","volume":"168","author":"Sakkas","year":"2002","journal-title":"J Immunol Baltim Md 1950"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib1040","first-page":"1751","article-title":"Type 2\u00a0helper T-cell predominance and high CD30\u00a0expression in systemic sclerosis","volume":"151","author":"Mavalia","year":"1997","journal-title":"Am J Pathol"},{"issue":"Suppl 3","key":"10.1016\/j.revmed.2019.05.016_bib1045","first-page":"iii33","article-title":"Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis","volume":"45","author":"Sunderk\u00f6tter","year":"2006","journal-title":"Rheumatol Oxf Engl"},{"issue":"11","key":"10.1016\/j.revmed.2019.05.016_bib1050","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17\u00a0production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.revmed.2019.05.016_bib1055","doi-asserted-by":"crossref","first-page":"e85032","DOI":"10.1371\/journal.pone.0085032","article-title":"IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway","volume":"8","author":"Xing","year":"2013","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.revmed.2019.05.016_bib1060","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00296-011-2056-y","article-title":"Th17\u00a0peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study","volume":"32","author":"Rodr\u00edguez-Reyna","year":"2012","journal-title":"Rheumatol Int"},{"issue":"9","key":"10.1016\/j.revmed.2019.05.016_bib1065","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/art.11129","article-title":"Systemic sclerosis Th2\u00a0cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha","volume":"48","author":"Chizzolini","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.revmed.2019.05.016_bib1070","first-page":"1202","article-title":"Macrophage infiltration in the skin of patients with systemic sclerosis","volume":"19","author":"Ishikawa","year":"1992","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.revmed.2019.05.016_bib1075","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/arrd.1985.131.4.612","article-title":"Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis","volume":"131","author":"Rossi","year":"1985","journal-title":"Am Rev Respir Dis"},{"issue":"12","key":"10.1016\/j.revmed.2019.05.016_bib1080","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.revmed.2019.05.016_bib1085","article-title":"M1\/M2\u00a0polarisation state of M-CSF blood-derived macrophages in systemic sclerosis","author":"Lescoat","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.revmed.2019.05.016_bib1090","first-page":"2628","article-title":"Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W\/W(V) mice","volume":"26","author":"Yamamoto","year":"1999","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib1095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/ard.2010.133587","article-title":"Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6\u00a0trans-signalling: a novel target for systemic sclerosis?","volume":"70","author":"Barnes","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.revmed.2019.05.016_bib1100","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar4672","article-title":"Targeting IL-6\u00a0by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis","volume":"16","author":"Desallais","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib1105","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.revmed.2019.05.016_bib1110","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib1115","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.revmed.2019.05.016_bib1120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A Randomized, Controlled Trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.05.016_bib1125","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.semarthrit.2018.03.019","article-title":"Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus","volume":"48","author":"Ingegnoli","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.revmed.2019.05.016_bib1130","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib1135","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.revmed.2019.05.016_bib2575","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1\u00a0and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319305259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319305259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:41:04Z","timestamp":1759336864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866319305259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":115,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0248866319305259"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.05.016","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s dans la physiopathologie de la scl\u00e9rodermie syst\u00e9mique\u00a0: vers de nouvelles opportunit\u00e9s th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}